Insmed (INSM) Net Income towards Common Stockholders (2010 - 2026)

Insmed's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$163.6 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 36.25% year-over-year to -$163.6 million in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 16.83% decrease from a year earlier, with the FY2025 full-year figure at -$1.3 billion, down 39.73% from the prior year.
• Net Income towards Common Stockholders advanced to -$163.6 million in Q1 2026 per INSM's latest filing, from -$328.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$94.6 million in Q1 2022 and bottomed at -$370.0 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$186.1 million (2023), against an average of -$210.9 million.
• Across the five-year window, Net Income towards Common Stockholders sank 155.96% in 2023 and soared 36.25% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$160.1 million in 2022, then retreated by 16.2% to -$186.1 million in 2023, then decreased by 26.6% to -$235.5 million in 2024, then tumbled by 39.46% to -$328.5 million in 2025, then surged by 50.21% to -$163.6 million in 2026.
• Per Business Quant, the three latest INSM Net Income towards Common Stockholders figures stand at -$163.6 million (Q1 2026), -$328.5 million (Q4 2025), and -$370.0 million (Q3 2025).